Full text is available at the source.
The lancet. Diabetes & endocrinology···
Safety and effectiveness of tirzepatide added to one oral diabetes medicine in Japanese patients with type 2 diabetes
Updated
Abstract
Among 443 participants with type 2 diabetes, 90% completed a 52-week trial of tirzepatide.
- Treatment-emergent adverse events occurred in 77% of participants, with higher rates in those receiving 15 mg of tirzepatide compared to lower doses.
- Common adverse events included mild or moderate nasopharyngitis, nausea, constipation, diarrhea, and decreased appetite.
- Mean bodyweight reductions at week 52 were -3.8 kg, -7.5 kg, and -10.2 kg for the 5 mg, 10 mg, and 15 mg tirzepatide groups, respectively.
- HbA1c levels decreased significantly from baseline to week 52, with reductions of 2.5% in the 5 mg group and 3.0% in both the 10 mg and 15 mg groups.
- No adjudication-confirmed deaths were reported during the study.
Simplified
BACKGROUND: Due to potential ethnic differences in the pathophysiology of type 2 diabetes, new therapeutics need to be evaluated in Japanese patients. We aimed to assess the safety and glycaemic efficacy of tirzepatide as an add-on treatment in Japanese patients with type 2 diabetes who had inadequate glycaemic control with stable doses of various oral antihyperglycaemic monotherapies.
METHODS: This multicentre, open-label, parallel-group, randomised, phase 3 trial was conducted at 34 medical research centres and hospitals in Japan. Eligible participants were aged 20 years or older with inadequately controlled (HbA≥7·0% to <11·0%) type 2 diabetes and were receiving oral antihyperglycaemic monotherapy (sulfonylureas, biguanides, α-glucosidase inhibitors, thiazolidinedione, glinides, or SGLT2 inhibitors) for at least 3 months (stable dose for ≥8 weeks before screening), had a BMI of 23 kg/mor higher, and stable bodyweight (±5%) for at least 3 months before screening. After a 2-week screening and 2-week lead-in period, all participants were randomly assigned (1:1:1) to receive 5, 10, or 15 mg of tirzepatide, administered once per week subcutaneously for 52 weeks followed by a 4 week safety follow-up period, using a computer-generated random sequence and interactive web response system, stratified by oral antihyperglycaemic medication group. All participants started receiving 2·5 mg tirzepatide and doses were escalated by 2·5 mg every 4 weeks until the assigned dose was reached. The primary endpoint was safety and tolerability during 52 weeks of treatment, assessed as incidence of treatment-emergent adverse events in the modified intention-to-treat (mITT) population. This trial is registered with ClinicalTrials.gov, NCT03861039. 1c2
FINDINGS: Between March 30, 2019, and Feb 16, 2021, with recruitment and enrolment continuing until Feb 4, 2020, 484 participants were assessed for eligibility and 443 were randomly assigned to receive at least one dose of tirzepatide (148 [33%] in the 5 mg group, 147 [33%] in the 10 mg group, and 148 [33%] in the 15 mg group). 398 (90%) participants completed the study and treatment. Most participants (343 [77%] of 443) had at least one treatment-emergent adverse event. Treatment-emergent adverse events were more frequent in the tirzepatide 15 mg group (125 [84%] of 148) than the 5 mg (109 [74%] of 148) and 10 mg groups (109 [74%] of 147). The most frequent treatment-emergent adverse events with tirzepatide were mild or moderate nasopharyngitis (75 [17%]), nausea (74 [17%]), constipation (54 [12%]), diarrhoea (51 [12%]), and decreased appetite (44 [10%]). At week 52, mean changes from baseline in bodyweight were -3·8 kg (SE 0·5; -5·1% reduction) in the 5 mg group, -7·5 kg (0·5; -10·1% reduction) in the 10 mg group, and -10·2 kg (0·5; -13·2% reduction) in the 15 mg group. Least squares mean HbAat baseline reduced from 8·5% (SE 0·1) to 6·0% (0·1) in the 5 mg tirzepatide group, from 8·6% (0·1) to 5·6% (0·1) in the 10 mg group, and from 8·6% (0·1) to 5·6% (0·1) in the 15 mg group at week 52. No adjudication-confirmed deaths were reported. 1c
INTERPRETATION: Tirzepatide was well tolerated as an add-on to oral antihyperglycaemic monotherapy in Japanese participants with type 2 diabetes and showed improvement in glycaemic control and bodyweight, irrespective of background oral antihyperglycaemic medication. Tirzepatide is a potential new treatment option for Japanese patients with type 2 diabetes that is inadequately controlled with single oral antihyperglycaemic medication.
FUNDING: Eli Lilly and Company.
TRANSLATION: For the Japanese translation of the abstract see Supplementary Materials section.
Related papers
Aug '22
Effectiveness and safety of tirzepatide alone versus dulaglutide in Japanese adults with type 2 diabetes
top 1% journal
cited by 190 papers
randomized controlled trial
Aug '21
Weekly tirzepatide compared to daily insulin as add-on treatments for type 2 diabetes with metformin, with or without SGLT2 inhibitors
top 1% journal
cited by 536 papers
randomized controlled trial
Apr '22
Tirzepatide compared to placebo or semaglutide on insulin production and sensitivity in adults with type 2 diabetes
top 1% journal
cited by 219 papers
randomized controlled trial
Jun '21
Effectiveness and safety of tirzepatide, a new drug activating two blood sugar control systems, in people with type 2 diabetes
top 1% journal
cited by 876 papers
randomized controlled trial
Jun '23
Weekly Tirzepatide for Treating Obesity in People with Type 2 Diabetes
top 1% journal
cited by 571 papers
randomized controlled trial
Oct '21
Tirzepatide compared to insulin glargine in type 2 diabetes patients with higher heart risk
top 1% journal
cited by 544 papers
clinical trial, phase iii
Apr '22
Weekly tirzepatide compared to daily insulin degludec for blood sugar control in adults with type 2 diabetes measured by continuous glucose monitoring
top 1% journal
cited by 51 papers
randomized controlled trial
Oct '18
Safety and effectiveness of LY3298176, a new drug targeting two hormone receptors, in people with type 2 diabetes: a controlled phase 2 trial
top 1% journal
cited by 714 papers
randomized controlled trial
Apr '22
Tirzepatide versus insulin degludec effects on liver fat and belly fat in people with type 2 diabetes
top 1% journal
cited by 417 papers
randomized controlled trial
Jun '23
Retatrutide, a drug targeting three hormone receptors, for people with type 2 diabetes in a controlled US clinical trial
top 1% journal
cited by 344 papers
randomized controlled trial